vs
Amarin Corp plc（AMRN）与STEM, INC.（STEM）财务数据对比。点击上方公司名可切换其他公司
STEM, INC.的季度营收约是Amarin Corp plc的1.0倍（$47.1M vs $45.1M），Amarin Corp plc净利率更高（-23.3% vs -33.9%，领先10.6%），Amarin Corp plc同比增速更快（7.0% vs -15.6%），过去两年STEM, INC.的营收复合增速更高（36.1% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
该公司是一家公开上市的生物制药企业，总部位于加利福尼亚州纽瓦克，专注研发纯化人类神经干细胞，旨在治疗中枢神经系统疾病与瘫痪，其所研发的神经干细胞可分化为中枢神经系统的神经元、星形胶质细胞与少突胶质细胞这三大主要细胞类型。
AMRN vs STEM — 直观对比
营收规模更大
STEM
是对方的1.0倍
$45.1M
营收增速更快
AMRN
高出22.6%
-15.6%
净利率更高
AMRN
高出10.6%
-33.9%
两年增速更快
STEM
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $47.1M |
| 净利润 | $-10.5M | $-16.0M |
| 毛利率 | — | 48.9% |
| 营业利润率 | 35.5% | -17.7% |
| 净利率 | -23.3% | -33.9% |
| 营收同比 | 7.0% | -15.6% |
| 净利润同比 | 33.0% | 68.8% |
| 每股收益（稀释后） | — | $-4.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNSTEM
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $47.1M | ||
| Q3 25 | $49.7M | $38.2M | ||
| Q2 25 | $72.7M | $38.4M | ||
| Q1 25 | $42.0M | $32.5M | ||
| Q4 24 | $62.3M | $55.8M | ||
| Q3 24 | $42.3M | $29.3M | ||
| Q2 24 | $67.5M | $34.0M |
净利润AMRNSTEM
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $-16.0M | ||
| Q3 25 | $-7.7M | $-23.8M | ||
| Q2 25 | $-14.1M | $202.5M | ||
| Q1 25 | $-15.7M | $-25.0M | ||
| Q4 24 | $-48.6M | $-51.1M | ||
| Q3 24 | $-25.1M | $-148.3M | ||
| Q2 24 | $1.5M | $-582.3M |
毛利率AMRNSTEM
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | 48.9% | ||
| Q3 25 | 44.7% | 35.5% | ||
| Q2 25 | 69.2% | 33.4% | ||
| Q1 25 | 59.8% | 32.4% | ||
| Q4 24 | -15.4% | -4.4% | ||
| Q3 24 | 38.5% | 21.2% | ||
| Q2 24 | 63.4% | 27.6% |
营业利润率AMRNSTEM
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | -17.7% | ||
| Q3 25 | -22.4% | -33.6% | ||
| Q2 25 | -22.0% | -34.8% | ||
| Q1 25 | -39.9% | -65.0% | ||
| Q4 24 | -84.3% | -84.4% | ||
| Q3 24 | -59.5% | -493.2% | ||
| Q2 24 | -0.8% | -1705.5% |
净利率AMRNSTEM
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | -33.9% | ||
| Q3 25 | -15.6% | -62.2% | ||
| Q2 25 | -19.4% | 527.8% | ||
| Q1 25 | -37.4% | -76.9% | ||
| Q4 24 | -78.0% | -91.6% | ||
| Q3 24 | -59.4% | -506.3% | ||
| Q2 24 | 2.3% | -1712.6% |
每股收益（稀释后）AMRNSTEM
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $-4.40 | ||
| Q3 25 | $-0.02 | $-2.84 | ||
| Q2 25 | $-0.03 | $-1.79 | ||
| Q1 25 | $-0.04 | $-0.15 | ||
| Q4 24 | $-0.12 | $-15.29 | ||
| Q3 24 | $-0.06 | $-18.24 | ||
| Q2 24 | $0.00 | $-71.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $48.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $-249.4M |
| 总资产 | $645.8M | $308.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRNSTEM
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $48.9M | ||
| Q3 25 | $286.6M | $43.1M | ||
| Q2 25 | $298.7M | $40.8M | ||
| Q1 25 | $281.8M | $58.6M | ||
| Q4 24 | $294.2M | $56.3M | ||
| Q3 24 | $305.7M | $75.4M | ||
| Q2 24 | $306.7M | $89.6M |
股东权益AMRNSTEM
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $-249.4M | ||
| Q3 25 | $458.9M | $-235.7M | ||
| Q2 25 | $464.9M | $-214.1M | ||
| Q1 25 | $473.7M | $-417.5M | ||
| Q4 24 | $486.2M | $-398.4M | ||
| Q3 24 | $531.4M | $-344.1M | ||
| Q2 24 | $551.9M | $-203.2M |
总资产AMRNSTEM
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $308.9M | ||
| Q3 25 | $659.8M | $362.6M | ||
| Q2 25 | $670.1M | $379.2M | ||
| Q1 25 | $655.7M | $405.1M | ||
| Q4 24 | $685.3M | $437.4M | ||
| Q3 24 | $750.6M | $537.8M | ||
| Q2 24 | $799.9M | $691.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $8.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRNSTEM
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $8.2M | ||
| Q3 25 | $-12.7M | $11.4M | ||
| Q2 25 | $16.6M | $-21.3M | ||
| Q1 25 | $-12.5M | $8.5M | ||
| Q4 24 | $-13.3M | $-14.7M | ||
| Q3 24 | $-2.4M | $-9.4M | ||
| Q2 24 | $-2.7M | $-11.9M |
现金转化率AMRNSTEM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
STEM
暂无分部数据
